Edition:
United States

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

36.14USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$36.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
245,262
52-wk High
$53.70
52-wk Low
$19.23

Summary

Name Age Since Current Position

William Doyle

55 2016 Executive Chairman of the Board

Asaf Danziger

51 2012 Chief Executive Officer, Director

Kinyip Leung

56 Vice Chairman of the Board

Wilhelmus Groenhuysen

60 2012 Chief Financial Officer

Michael Ambrogi

54 Chief Operating Officer

Eilon Kirson

49 2012 Chief Science Officer and Head of Research and Development

Todd Longsworth

43 2016 General Counsel

Pritesh Shah

2018 Chief Commercial Officer

Jeryl Hilleman

2018 Director

William Burkoth

41 2009 Independent Director

David Hung

61 2018 Independent Director

Martin Madden

57 2017 Independent Director

Sherilyn McCoy

59 2018 Independent Director

Charles Phillips

69 2012 Independent Director

William Vernon

62 2006 Lead Independent Director

Biographies

Name Description

William Doyle

Mr. William F. Doyle is Executive Chairman of the Board of the Novocure Ltd. Mr. Doyle has served as Chairman of the Board since 2009 and has been a director of Novocure since 2004. Mr. Doyle has also been the Managing Director of WFD Ventures LLC, a private venture capital firm he co-founded, since 2002 and was formerly a member of the investment team at Pershing Square Capital Management L.P., a private investment firm. Prior to 2002, Mr. Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, Worldwide President of Biosense-Webster, Inc. and a member of the boards of Cordis Corporation and Johnson & Johnson Development Corporation, Johnson & Johnson’s venture capital subsidiary. From 1992 to 1995, Mr. Doyle was a management consultant in the healthcare group of McKinsey & Company. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Asaf Danziger

Mr. Asaf Danziger is Chief Executive Officer, Director of the Novocure Ltd . He has served as our Chief Executive Officer since 2002 and has been a director of NovoCure since 2012. From 1998 to 2002, Mr. Danziger was CEO of Cybro Medical, a subsidiary of Imagyn Medical Technologies, Inc. Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.

Kinyip Leung

Mr. Kinyip Gabriel Leung is Vice Chairman of the Board of the Company. He has been Vice Chairman and a director of Novocure since 2011. Mr. Leung retired as Executive Vice President of OSI Pharmaceuticals, Inc. and as the President of OSI’s Oncology and Diabetes Business following OSI’s acquisition by Astellas Pharma Inc. in 2010. Mr. Leung was responsible for the launch of Tarceva (erlotinib) at OSI Pharmaceuticals, guiding the product to the most successful launch in U.S. oncology history with global sales exceeding $1.2 billion in 2009. Prior to his tenure at OSI, Mr. Leung served as Group Vice President of the Global Prescription Business at Pharmacia Corporation from 1999 to 2003, leading Pharmacia’s oncology franchise with business and medical affairs operations in over 80 countries. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company. Mr. Leung currently serves on the board of Pernix Therapeutics Holdings, Inc. and previously served on the boards of Albany Molecular Research Inc. and Delcath Systems, Inc. Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. Mr. Leung earned his M.S. in Pharmacy from the University of Wisconsin-Madison, with a concentration in pharmaceutical marketing.

Wilhelmus Groenhuysen

Mr. Wilhelmus C. M. Groenhuysen is Chief Financial Officer of the company. He has been our Chief Financial Officer since 2012. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as executive vice president and chief financial officer, where he had responsibility for worldwide finance, commercial operations and risk management. From 1987 to 2007, Mr. Groenhuysen worked for Philips Group in various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to chief financial officer and senior vice president of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master’s Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.

Michael Ambrogi

Mr. Michael J. Ambrogi is Chief Operating Officer of the company. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing and service and human resources activities worldwide. From 1991 to 2006, Mr. Ambrogi worked for Deka Research and Development Corporation, inventor Dean Kamen’s research and development firm, last serving a general manager. Mr. Ambrogi led Deka’s teams on many products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent and the J&J IBOT 3000 mobility system. Earlier in his career, from 1988 to 1990, Mr. Ambrogi was a consultant with McKinsey & Company, a global management consultant firm.. Mr. Ambrogi holds a S.B. in mechanical engineering from MIT.

Eilon Kirson

Mr. Eilon D. Kirson, M.D., Ph.D. is Chief Science Officer and Head of Research and Development of the Company. He has been our Chief Science Officer and Head of Research and Development since 2012 and previously served as our Chief Medical Officer from 2006 to 2012. Dr. Kirson has led the development of TTFields from pre-clinical testing to large, multi-center phase 3 studies and through multiple regulatory approvals. Dr. Kirson previously served as head of electrophysiology at Carmel Biosensors Ltd., a company which developed medical monitoring sensors. Dr. Kirson received his B.Med.Sc., M.D. and Ph.D. in Physiology-Biophysics from the Hebrew University of Jerusalem and served his residency in neurology at Sheba Medical Center, Tel Ha-Shomer Hospital, Israel.

Todd Longsworth

Mr. Todd Longsworth is General Counsel of the Company. He joined Novocure in April 2012 and serves as General Counsel and Chief Compliance Officer. Mr. Longsworth worked for Cephalon, Inc., a U.S. biopharmaceutical company, from 2005 to 2012, last serving as Mergers and Acquisitions, Securities and Corporate Governance Counsel. Prior to joining Cephalon, he was an associate at WilmerHale LLP, a global law firm from 2001 to 2005. Mr. Longsworth earned his B.A. from Duke University and his J.D. from the University of Pennsylvania.

Pritesh Shah

Mr. Pritesh Shah is Chief Commercial Officer of the Company. Mr. Shah served as the Company’s Senior Vice President, Americas since March 2016, as General Manager, US from January 2014 to March 2016 and he has held other sales and marketing roles with the Company since 2012. Prior to joining Novocure, Mr. Shah had extensive experiences in leading Oncology commercial and medical affairs functions at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology and AVEO Oncology. Mr. Shah holds a Doctor of Pharmacy from the University of Maryland and a master’s degree in Strategic Communication and Leadership from Seton Hall University.

Jeryl Hilleman

William Burkoth

Mr. William Burkoth is Independent Director of the Company. He has been a director of Novocure since 2009 and has served on our nominating and corporate governance committee since 2015. Mr. Burkoth has worked for Pfizer Inc.’s Venture Investments Team since 2004, currently serving as Executive Director, where he has responsibility for making direct equity investments in private life-science companies on behalf of Pfizer Inc. Prior to joining Pfizer Inc., from 2002 to 2004, Mr. Burkoth worked in business development at the pharmaceutical companies Galileo Pharmaceuticals, Inc. and IntraBiotics Pharmaceuticals, Inc. From 1999 to 2002, Mr. Burkoth worked as an analyst at Bay City Capital, a life sciences venture capital firm. Mr. Burkoth currently serves as a director for private companies Biodesy, Inc., G-CON Manufacturing Inc., NeuMoDx Molecular, Inc., and RefleXion Medical Inc. Mr. Burkoth received a B.A. in chemistry from Whitman College and an M.B.A. from Columbia Business School.

David Hung

Dr. David T. Hung, M.D. is Independent Director of the Company. Dr. Hung was founder, president and chief executive officer of Medivation, Inc., from 2004 to 2016. Medivation developed and commercialized Xtandi for the treatment of metastatic and non-metastatic prostate cancer, driving the program from invention to FDA approval in seven years, one of the fastest development times in biopharmaceutical history. By 2016, Xtandi had become the world’s leading prostate cancer therapy, with nearly $2.5 billion in annual revenue. Dr. Hung brings extensive industry experience in the development and commercialization of cancer therapies. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine and an A.B. in Biology from Harvard College.

Martin Madden

Mr. Martin J. Madden is an Independent Director of the Company. Mr. Madden has been a director of Novocure since 2017. Mr. Madden recently retired after a 30-year career at Johnson & Johnson (from 1986 to 2017), where he most recently served as Vice President of R&D for DePuy-Synthes and Vice President of Medical Device R&D Transformation from February 2016 to January 2017; as Vice President of New Product Development, Medical Devices from July 2015 to February 2016; and as Vice President of R&D for the Global Surgery Group from January 2012 to July 2015. Earlier in his career, Mr. Madden was a medical device engineer and innovator and a leader of cross-functional teams charged with incubating, developing, and launching new products. He also serves on the board of Microbot Medical Inc. Mr. Madden graduated summa cum laude with a Bachelor’s degree in Mechanical Engineering from the University of Dayton, earned a Master’s degree with honors in Mechanical Engineering from Carnegie-Mellon University, and graduated first in his class with honors from Columbia University’s M.B.A. program.

Sherilyn McCoy

Ms. Sherilyn D. McCoy is Independent Director of the Company. Ms. McCoy was chief executive officer of Avon Products, Inc., a direct selling company in beauty, household and personal care categories, from 2012 to 2018. Prior to joining Avon, Ms. McCoy had various roles at Johnson & Johnson, most recently serving as vice chairman of the executive committee and member of the office of the chairman, where she was responsible for the pharmaceutical and consumer business divisions of the company. She brings substantial general business leadership and innovation knowledge and experience as a senior leader of two global Fortune 500 companies. Ms. McCoy holds a B.A. in textile chemistry from the University of Massachusetts, Dartmouth, a master’s degree in chemical engineering from Princeton University, and an MBA from Rutgers University. Ms. McCoy is also a director of AstraZeneca, PLC and Stryker Corporation.

Charles Phillips

Mr. Charles G. Phillips III is an Independent Director of the Company. He has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012. From 2008 to 2011, Mr. Phillips served as Chief Operating Officer of Prentice Capital Management, LLC, a private investment management firm. Previously, Mr. Phillips was a managing director from 1991 to 2002 and President from 1998 to 2001 of Gleacher & Co. , an investment banking and management firm. Prior to joining Gleacher & Co., Mr. Phillips held senior positions at other leading investment banking firms, including nine years at Morgan Stanley, where he served as a managing director within the investment banking division and founded the firm’s high-yield finance activities. Mr. Phillips has served on the boards of several public and private companies and private investment funds, including California Pizza Kitchen, Inc. and Fidus Investment Corporation, and he has also served on the governing bodies of a number of educational and non-profit organizations. Mr. Phillips earned an A.B. from Harvard College and an M.B.A from Harvard Business School.

William Vernon

Mr. William A. (Tony) Vernon is an Lead Independent Director of the Company. He has been a director of Novocure since 2006, serving on our compensation committee since 2012 and as chairperson of our nominating and corporate governance committee since 2015. Mr. Vernon served as the Chief Executive Officer of the Kraft Foods Group, a food products company, from 2012 to 2014 and served as a senior advisor through May 2015. From 2009 to 2011, Mr. Vernon served as the President of Kraft Foods North America and as an Executive Vice President of Kraft Foods. From 2006 to 2009, Mr. Vernon served as the healthcare industry partner for Ripplewood Holdings, a private equity firm. From 1982 to 2005, Mr. Vernon worked for Johnson & Johnson in a variety of leadership roles, including as Company Group Chairman of DePuy Orthopaedics, President of Centocor Biologics, President of McNeil Consumer Products and Nutritionals, and President of The Johnson & Johnson-Merck Joint Venture. Mr. Vernon currently serves on the boards of Axovant Sciences, Intersect ENT Inc. and The WhiteWave Foods Company, and he previously served on the board of the Kraft Foods Group from 2012 to 2015. Mr. Vernon holds a B.A. in history from Lawrence University and an M.B.A. from Northwestern University’s Kellogg School of Management.

Basic Compensation